The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy Volunteers

The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy Volunteers

To investigate the hemodynamic effects of PACAP38 after glibenclamide administration.

22 healthy participants will randomly be allocated to receive PACAP38 infusion followed by glibenclamide or placebo on two different days.

The aim of the study is to investigate the vascular effect of PACAP38 after glibenclamide administration.

Repeated measurements covering the arteria radialis (RA), superficial temporal artery (STA) and middle cerebral artery (MCA) before and after PACAP38 infusion and glibenclamide/placebo administration

Inclusion Criteria:

• Healthy volunteers of both sexes.
• 18-60 years.
• 50-100 kg.
• Women of childbearing age must use adequate contraception

Exclusion Criteria:

• A history of serious somatic or psychiatric disease
• Migraine or any other type of headache (except episodic tension-type headache less than 5 days per month)
• Daily intake of any medication except contraceptives